Advanced search
Publication Cover
Current Medical Research and Opinion Volume 36, 2020 - Issue 5
Submit an article Journal homepage
6,229
Views
6
CrossRef citations to date
0
Altmetric
Psychiatry

Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder

Gang WangBeijing An Ding Hospital, Capital Medical University, China National Clinical Research Center for Mental Disorders, Beijing, China;
,
Kun ZhaoDivision of Health Technology Assessment and Policy Evaluation, China National Health Development Research Center (CHNHDR), National Health Commission, Beijing, China;
,
Caroline Reynaud-MouginH Lundbeck A/S, Valby, Denmark
,
Henrik LoftH Lundbeck A/S, Valby, Denmark
,
Hongye RenH Lundbeck A/S, Valby, Denmark
,
Hanne-Lise F. EriksenH Lundbeck A/S, Valby, Denmark
&
Anders EttrupH Lundbeck A/S, Valby, DenmarkCorrespondence[email protected]
 show all
Pages 875-882 | Received 29 Aug 2019, Accepted 23 Jan 2020, Published online: 13 Feb 2020

Figures & data

Table 1. Demographic and clinical sample characteristics.

Figure 1. Successfully treated patients (STPs) at week 8 by treatment group.

*p < .05. Treated patients; last observation carried forward. STP Mood and Tolerability: vortioxetine n = 61/211; venlafaxine, n = 45/226; STP Mood and Functioning: vortioxetine n = 59/211; venlafaxine, n = 53/226.

Abbreviations. MADRS, Montgomery–Åsberg Depression Rating Scale; SDS, Sheehan Disability Scale; STP, Successfully treated patient; TEAE, Treatment-emergent adverse event; XR, Extended release.

Figure 1. Successfully treated patients (STPs) at week 8 by treatment group.*p < .05. Treated patients; last observation carried forward. STP Mood and Tolerability: vortioxetine n = 61/211; venlafaxine, n = 45/226; STP Mood and Functioning: vortioxetine n = 59/211; venlafaxine, n = 53/226.Abbreviations. MADRS, Montgomery–Åsberg Depression Rating Scale; SDS, Sheehan Disability Scale; STP, Successfully treated patient; TEAE, Treatment-emergent adverse event; XR, Extended release.

Table 2. Summary of drug costs, treatment outcomes and base case results.

Table 3. Clinical sensitivity results.

Table 4. Region sensitivity results, brand and generic prices.

Supplemental material

Supplemental Material

Download PDF (5.6 KB)

Data availability

The authors confirm that the data supporting the findings of this study are available within the article. The authors may be contacted for further data sharing.

Related Research Data

Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review
Source: Springer Nature
Restoring function in major depressive disorder: A systematic review.
Source: Elsevier BV
Psychosocial impairment and recurrence of major depression
Source: Elsevier
Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
Source: Physicians Postgraduate Press, Inc
Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Source: Elsevier BV
Risk factors and predictors of compliance in depression
Source: Elsevier BV
Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance
Source: Wiley
Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
Source: Informa UK Limited
Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder
Source: Elsevier BV
A new depression scale designed to be sensitive to change.
Source: Royal College of Psychiatrists
Incorporating Multidimensional Patient-Reported Outcomes of Symptom Severity, Functioning, and Quality of Life in the Individual Burden of Illness Index for Depression to Measure Treatment Impact and Recovery in MDD
Source: American Medical Association (AMA)
Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.
Source: American Psychiatric Association Publishing
Association between antidepressant side effects and functional impairment in patients with major depressive disorders.
Source: Elsevier BV
Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study
Source: Informa Healthcare
Depression hurts, depression costs: The medical spending attributable to depression and depressive symptoms in China.
Source: Wiley
Remission, Recovery, Relapse, and Recurrence
Source: American Medical Association (AMA)
Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland
Source: Informa UK Limited
Defining remission by cut off score on the MADRS: selecting the optimal value.
Source: Elsevier BV
The measurement of disability.
Source: Ovid Technologies (Wolters Kluwer Health)
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Source: Ovid Technologies (Wolters Kluwer Health)
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale
Source: Ovid Technologies (Wolters Kluwer Health)
Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Source: Informa UK Limited
How should remission from depression be defined? The depressed patient's perspective.
Source: American Psychiatric Association Publishing
What is important in being cured from depression? Discordance between physicians and patients (1).
Source: Elsevier BV
The recovery index: A novel approach to measuring recovery and predicting remission in major depressive disorder.
Source: Elsevier BV
Remission in depressed outpatients: more than just symptom resolution?
Source: Elsevier BV
Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D)
Source: Elsevier BV
A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder.
Source: Oxford University Press (OUP)

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.